Sticky post

Tetra Bio-Pharma first-past-the-post on clinical trial for chronic pain

Tetra Bio-Pharma and clinical research partner Santé Cannabis conduct first-ever and most exhaustive clinical trial to evaluate safety and efficacy of different doses and ratios of cannabis oils versus placebo for (non-cancer) chronic pain. On track for completion later this fall.
Continue reading Tetra Bio-Pharma first-past-the-post on clinical trial for chronic pain

Sticky post

Can THC treat inflammatory bowel disease? We’re about to find out.

Researchers have discovered that cannabis is frequently used to alleviate diarrhea, abdominal pain, and loss of appetite caused by inflammatory bowel disease.

Several clinical trials are planned or underway to assess the effectiveness of THC and CBD in treating these conditions, such a Crohn’s and colitis. Continue reading Can THC treat inflammatory bowel disease? We’re about to find out.

Health Canada makes Tetra Bio-Pharma cannabis-delivery product a Class Two medical device.

Heath Canada decision to reclassify, to a Phase Two medical device, the @TetraBioPharma inhalation pipe for cannabis medication means that patients suffering cancer pain may soon be able to claim the cost through their private and public insurance plans. Continue reading Health Canada makes Tetra Bio-Pharma cannabis-delivery product a Class Two medical device.

Sticky post

Aphria signs deal; exclusive global partner for QuickStrip

Aphria and Canadian bio-technology company Rapid Dose Therapeutics have signed an MOU that Aphria will have exclusive global preferred rights to produce, distribute and sell QuickStrip(TM) products for cannabis markets around the world, once a definitive agreement is signed between the two companies in the near future. Continue reading Aphria signs deal; exclusive global partner for QuickStrip

On heels of FDA approval for its CBD epilepsy drug, GW Pharm continues focus on schizophrenia & other “incurable” diseases

Drug company earning multi-millions on MS med containing only 2 ingredients – THC and CBD ready to launch epilepsy drug this fall & now racing to develop CBD drugs for schizophrenia, #autism & other hard-to treat diseases. Continue reading On heels of FDA approval for its CBD epilepsy drug, GW Pharm continues focus on schizophrenia & other “incurable” diseases

Sticky post

Supreme Cannabis joins “Big Six” club; New supply agreements & exclusive “premium” listing.

The only major cannabis producer exclusively listing  as a premium offering, @Supreme Cannabis holds supply agreements with 6 provinces.

The company today announced new agreements with Nova Scotia and PEI.  Continue reading Supreme Cannabis joins “Big Six” club; New supply agreements & exclusive “premium” listing.

Namaste strikes bulk-supply deal to feed online sales; first LP with sales-only licence

A bulk cannabis-supply agreement between Namaste and Kelowna-based GreenTec Bio-Pharmaceuticals is giving Namaste subsidiary Cannmart a big leg up in the budding online-sales space as the company will be the first Health-Canada approved License Producer with a “sales only” license. Continue reading Namaste strikes bulk-supply deal to feed online sales; first LP with sales-only licence

Sticky post

Man-made THC improves headache in clinical trials

Clues to the anti-headache mechanisms of cannabis can be found by looking at headache conditions that are relieved by reducing intracranial pressure.  Dexanabinol, a synthetic cannabinoid, has been found to relieve intracranial pressure and improve outcomes after traumatic brain injury. In addition, a double-blind, placebo-controlled trial of 26 patients found that a synthetic form of THC (Nabilone) was “significantly more effective” than Ibuprofen in reducing pain intensity. It was also suggested that the anti-vomiting properties seen in the treatment of nausea brought on by chemotherapy might also be effective in treating migraine. Copyright Notice ©CannabisFindings.com. 2018. Unauthorized use and/or duplication … Continue reading Man-made THC improves headache in clinical trials